Showing results (291-300 of 408) with videos related to

Sort By:
Pageof 41
The Journal of Antimicrobial Chemotherapy|December 11, 2014
Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniaeDavid van Duin, Eric Cober, Sandra S Richter, et al.
Infection Control and Hospital Epidemiology|December 30, 2016
Which Comorbid Conditions Should We Be Analyzing as Risk Factors for Healthcare-Associated Infections?Anthony D Harris, Lisa Pineles, Deverick Anderson, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2025
Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemiaSavan Patel, Sana Mohayya, Arsheena Yassin, et al.
JMIR Mhealth and Uhealth|December 16, 2020
ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development StudyXueliang Hua, Chen Li, Jason M Pogue, et al.
The Journal of Antimicrobial Chemotherapy|January 29, 2019
The hypothetical impact of Accelerate Pheno™ system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identificationOryan Henig, Christopher C Cooper, Keith S Kaye, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|January 30, 2023
At the vanguard: Leaders' perspectives on establishing healthcare system infection prevention programsMichael P Stevens, Sharon B Wright, Keith S Kaye, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2004
Variety of beta-lactamases produced by amoxicillin-clavulanate-resistant Escherichia coli isolated in the northeastern United StatesKeith S Kaye, Howard S Gold, Mitchell J Schwaber, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 9, 2017
Electronically Available Comorbidities Should Be Used in Surgical Site Infection Risk AdjustmentSarah S Jackson, Surbhi Leekha, Laurence S Magder, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2020
Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial InfectionsKeith S Kaye, Helen W Boucher, Michelle L Brown, et al.
Open Forum Infectious Diseases|February 11, 2022
Daptomycin-Resistant Enterococcus Bacteremia Is Associated With Prior Daptomycin Use and Increased Mortality After Liver TransplantationRachael A Lee, Jason Goldman, Ghady Haidar, et al.
Pageof 41